Opus Genetics secures $2 million funding for MERTK program to develop gene therapies for retinitis pigmentosa.

Cyclacel Pharmaceuticals has announced a $3M securities purchase agreement with accredited investors to raise funds for general corporate purposes. The transaction includes warrants for common stock and is expected to extend the company's cash runway into Q3 2025. Analysts have given a mixed outlook on the stock, with a Buy rating and a $11.00 price target. However, the company's low financial performance score and negative P/E ratio make its valuation unattractive.